MaxCyte Q3 revenue down 16% YoY to $6.8M; reiterates FY2025 guidance

MAXCYTE, INC.

2025-Q3 EPS reported -$0.33 vs consensus -$0.11 ▼ miss (-194.1%)

Total revenue $6.8M (-16% YoY); core revenue $6.4M (-21% YoY).
Net loss $12.4M vs $11.6M loss in Q3 2024; adjusted EBITDA loss $10.0M.
Added 4 new SPL clients in 2025 (latest Moonlight Bio in Oct); total SPLs now 32.
Reiterates FY2025 guidance: core revenue flat/-10% YoY; SPL program revenue ~$5M.
Operational restructuring announced Sep 22 to reduce costs; cash at $158M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.